Opus Genetics, Inc. (IRD)
3.83
-0.01
(-0.26%)
USD |
NASDAQ |
Oct 19, 15:49
Opus Genetics EPS Diluted (Quarterly) : -0.139 for June 30, 2026
EPS Diluted (Quarterly) Chart
Historical EPS Diluted (Quarterly) Data
| Date | Value |
|---|---|
| June 30, 2026 | -0.139 |
| March 31, 2026 | -0.7542 |
| December 31, 2025 | -0.2364 |
| September 30, 2025 | -0.2471 |
| June 30, 2025 | -0.1171 |
| March 31, 2025 | -0.2418 |
| December 31, 2024 | -1.113 |
| September 30, 2024 | -0.2879 |
| June 30, 2024 | -0.3006 |
| March 31, 2024 | -0.2898 |
| December 31, 2023 | -0.2086 |
| September 30, 2023 | 0.2482 |
| June 30, 2023 | -0.2367 |
| March 31, 2023 | -0.2766 |
| December 31, 2022 | 1.580 |
| September 30, 2022 | -0.221 |
| June 30, 2022 | -0.2526 |
| March 31, 2022 | -0.3492 |
| December 31, 2021 | -0.3536 |
| September 30, 2021 | -0.2499 |
| June 30, 2021 | -0.5244 |
| March 31, 2021 | -3.572 |
| September 30, 2020 | -1.333 |
| June 30, 2020 | -2.499 |
| March 31, 2020 | -3.481 |
| Date | Value |
|---|---|
| December 31, 2019 | -1.86 |
| September 30, 2019 | -1.950 |
| June 30, 2019 | -2.453 |
| March 31, 2019 | -2.479 |
| December 31, 2018 | -4.32 |
| September 30, 2018 | -8.071 |
| June 30, 2018 | -5.76 |
| March 31, 2018 | -3.139 |
| December 31, 2017 | -5.76 |
| September 30, 2017 | -1.92 |
| June 30, 2017 | 1.44 |
| March 31, 2017 | -43.20 |
| December 31, 2016 | -1.061 |
| September 30, 2016 | -4.80 |
| June 30, 2016 | -4.80 |
| March 31, 2016 | -9.60 |
| December 31, 2015 | -6.936 |
| September 30, 2015 | -9.60 |
| June 30, 2015 | -9.60 |
| March 31, 2015 | -9.60 |
| December 31, 2014 | -5.952 |
| September 30, 2014 | -4.80 |
| June 30, 2014 | 0.5232 |
| March 31, 2014 | -43.20 |
| December 31, 2013 | -4.80 |
EPS Diluted (Quarterly) Range, Past 5 Years
--
Minimum
--
Maximum
--
Average
--
Median
EPS Diluted (Quarterly) Benchmarks
| Rezolute, Inc. | -0.1961 |
| Faeth Therapeutics, Inc. | -2.836 |
| Nuvectis Pharma, Inc. | -0.299 |
| ACADIA Pharmaceuticals, Inc. | 0.1822 |
| Alnylam Pharmaceuticals, Inc. | 1.207 |
EPS Diluted (Quarterly) Related Metrics
| Net Income (Quarterly) | -8.098M |
| Revenue (Quarterly) | 0.755M |
| Total Expenses (Quarterly) | 8.853M |
| Enterprise Value | 264.76M |
| Gross Profit Margin (Quarterly) | 98.15% |
| Profit Margin (Quarterly) | -1.07K% |
| Earnings Yield | -35.95% |
| Normalized Earnings Yield | -22.36 |